XML 22 R9.htm IDEA: XBRL DOCUMENT
v2.4.0.6

Consolidated Financial Statement Detail | 12 Months Ended
--- | ---
Dec. 31, 2012
Consolidated Financial Statement Detail [Abstract] |
Consolidated Financial Statement Detail |
3. | Consolidated Financial Statement Detail
Cash and Cash Equivalents At December 31, 2012, cash equivalents consisted of demand deposits of $7.8 million and money market funds of $37.5 million with maturities of less than 90 days at the date of purchase. At December 31, 2011, cash equivalents consisted of demand deposits of $21.1 million and money market funds of $27.2 million with maturities of less than 90 days at the date of purchase. Short-term Investments At December 31, 2012, short-term investments consisted of U.S. treasury securities of $40.0 million with maturities of greater than 90 days and less than one year from the date of purchase. At December 31, 2011, the Company did not have short-term investments. Foreign Exchange Options The Company holds debt and may incur revenue and expenses denominated in foreign currencies, which exposes it to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and the Euro. The Company is required in the future to make principal and accrued interest payments in Euros on its €15.0 million loan from Les Laboratoires Servier ("Servier") (See Note 7: Long-Term Debt and Other Arrangements). In order to manage its foreign currency exposure related to these payments, in May 2011, the Company entered into two foreign exchange option contracts to buy €1.5 million and €15.0 million in January 2014 and January 2016, respectively. By having these option contracts in place, the Company's foreign exchange rate risk is reduced if the U.S. dollar weakens against the Euro. However, if the U.S. dollar strengthens against the Euro, the Company is not required to exercise these options, but will not receive any refund on premiums paid. Upfront premiums paid on these foreign exchange option contracts totaled $1.5 million. The fair values of these option contracts are revalued at each reporting period and are estimated based on pricing models using readily observable inputs from actively quoted markets. The fair values of these option contracts are included in other assets on the consolidated balance sheet and changes in fair value on these contracts are included in other income (expense) on the consolidated statements of comprehensive loss. The foreign exchange options were revalued at December 31, 2012 and had an aggregate fair value of $0.5 million. The Company recognized losses of $0.7 million and $0.3 million related to the revaluation for the years ended December 31, 2012 and 2011, respectively. Receivables Receivables consisted of the following at December 31, 2012 and 2011 (in thousands):
|  | December 31, |
|  | 2012 |  |  | 2011 |
Trade receivables, net |  | $ | 7,477 |  |  | $ | 11,820 |
Other receivables |  |  | 772 |  |  |  | 512 |
Total |  | $ | 8,249 |  |  | $ | 12,332 |
Property and Equipment Property and equipment consisted of the following at December 31, 2012 and 2011 (in thousands):
|  | December 31, |
|  | 2012 |  |  | 2011 |
Equipment and furniture |  | $ | 25,734 |  |  | $ | 33,483 |
Buildings, leasehold and building improvements |  |  | 21,656 |  |  |  | 21,490 |
Construction-in-progress |  |  | 1,832 |  |  |  | 973 |
Land |  |  | 310 |  |  |  | 310 |
|  |  | 49,532 |  |  |  | 56,256 |
Less: Accumulated depreciation and amortization |  |  | (41,389 | ) |  |  | (43,547 | )
Property and equipment, net |  | $ | 8,143 |  |  | $ | 12,709 |
Depreciation and amortization expense was $4.1 million, $5.4 million and $5.7 million for the years ended December 31, 2012, 2011, and 2010, respectively. Accrued Liabilities Accrued liabilities consisted of the following at December 31, 2012 and 2011 (in thousands):
|  | December 31, |
|  | 2012 |  |  | 2011 |
Accrued clinical trial costs |  | $ | 4,702 |  |  | $ | 140 |
Accrued management incentive compensation |  |  | 3,802 |  |  |  | 4,096 |
Accrued payroll and other benefits |  |  | 2,461 |  |  |  | 3,007 |
Accrued severance payments |  |  | 490 |  |  |  | 1,207 |
Other |  |  | 1,535 |  |  |  | 1,562 |
Total |  | $ | 12,990 |  |  | $ | 10,012 |
Deferred Revenue In 2012, the Company deferred $5.9 million of revenue from contracts including Servier, and NIH and recognized $9.4 million in revenue. In 2011, the Company deferred $12.7 million of revenue from contracts including Servier, NIH and Takeda Pharmaceutical Company Limited ("Takeda") and recognized $17.6 million in revenue.

X
- Definition The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + References No definition available. + Details
Name: | us-gaap_AdditionalFinancialInformationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | xoma_ConsolidatedFinancialStatementDetailAbstract
Namespace Prefix: | xoma_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration